1. Home
  2. EXPO vs MIRM Comparison

EXPO vs MIRM Comparison

Compare EXPO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EXPO
  • MIRM
  • Stock Information
  • Founded
  • EXPO 1967
  • MIRM 2018
  • Country
  • EXPO United States
  • MIRM United States
  • Employees
  • EXPO N/A
  • MIRM N/A
  • Industry
  • EXPO Professional Services
  • MIRM Biotechnology: Pharmaceutical Preparations
  • Sector
  • EXPO Consumer Discretionary
  • MIRM Health Care
  • Exchange
  • EXPO Nasdaq
  • MIRM Nasdaq
  • Market Cap
  • EXPO 3.5B
  • MIRM 3.3B
  • IPO Year
  • EXPO 1990
  • MIRM 2019
  • Fundamental
  • Price
  • EXPO $70.05
  • MIRM $74.31
  • Analyst Decision
  • EXPO
  • MIRM Strong Buy
  • Analyst Count
  • EXPO 0
  • MIRM 10
  • Target Price
  • EXPO N/A
  • MIRM $74.20
  • AVG Volume (30 Days)
  • EXPO 499.6K
  • MIRM 752.1K
  • Earning Date
  • EXPO 10-23-2025
  • MIRM 11-11-2025
  • Dividend Yield
  • EXPO 1.71%
  • MIRM N/A
  • EPS Growth
  • EXPO N/A
  • MIRM N/A
  • EPS
  • EXPO 1.99
  • MIRM N/A
  • Revenue
  • EXPO $519,154,000.00
  • MIRM $429,161,000.00
  • Revenue This Year
  • EXPO $4.31
  • MIRM $53.08
  • Revenue Next Year
  • EXPO $7.48
  • MIRM $20.45
  • P/E Ratio
  • EXPO $35.20
  • MIRM N/A
  • Revenue Growth
  • EXPO 2.10
  • MIRM 62.33
  • 52 Week Low
  • EXPO $63.81
  • MIRM $36.86
  • 52 Week High
  • EXPO $115.75
  • MIRM $78.10
  • Technical
  • Relative Strength Index (RSI)
  • EXPO 45.37
  • MIRM 63.07
  • Support Level
  • EXPO $68.30
  • MIRM $73.70
  • Resistance Level
  • EXPO $71.01
  • MIRM $77.96
  • Average True Range (ATR)
  • EXPO 1.57
  • MIRM 2.48
  • MACD
  • EXPO -0.11
  • MIRM -0.54
  • Stochastic Oscillator
  • EXPO 33.33
  • MIRM 48.19

About EXPO Exponent Inc.

Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: